Coherus BioSciences Inc (NAS:CHRS)
$ 2.12 -0.05 (-2.3%) Market Cap: 243.22 Mil Enterprise Value: 464.61 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 42/100

Coherus BioSciences Inc Conference Call Transcript

Jan 22, 2024 / 01:30PM GMT
Release Date Price: $2.58 (+5.74%)
Operator

Ladies and gentlemen, thank you for standing by. Welcome to Coherus Ophthalmology franchise divestiture conference call. At this time, all participants are in a listen only mode because the speakers' presentation there will be a question-and-answer session to ask a question. (Operator Instructions)

Please be advised that today's conference is being recorded. I would like now to turn the conference over to Jami Taylor, Head of Investor Relations. Please go ahead.

Jami Taylor Coherus BioSciences Inc;Head of IR

Thank you, Michelle. Good morning, everyone, and thank you for joining us today. I am Jamie Taylor, Head of Investor Relations at Coherus. Earlier today, we issued a press release announcing the divestiture of our similarly ophthalmology franchise to Sandoz in a $170 million upfront all cash deal.

That announcement is the sole and primary topic of this call with us today to offer insight into this news is Denny Lanfear, Chairman and Chief Executive Officer of Coherus. Available during the Q&A portion of our call today are Bryan

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot